12/12/2011 - Lannett Receives FDA Approval For Triamterene With Hydrochlorothiazide 37.5/25 MG Capsules
Lannett Company, Inc. (NYSE AMEX: LCI) today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules.
Read More
Read More
12/07/2011 - Lannett To Present At Oppenheimer 22nd Annual Healthcare Conference on December 14th
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the company will present at the Oppenheimer 22nd Annaul Healthcare Conference on Wednesday, December 14, 2011 at 11:25 a.m. ET at the Waldorf Astoria Hotel in New York City.
Read More
View the Webcast
11/10/2011 - Lannett To Present At Lazard Capital Markets 8th Annual Healthcare Conference On November 15th
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the company will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15, 2011 at 8 a.m. ET at the Pierre Hotel in New York City.
Read More
View the Webcast
11/03/2011 - Lannett Reports Improved Results For Fiscal 2012 First Quarter
Lannett Company, Inc. (NYSE Amex: LCI)today reported increased sales and income for the fiscal 2012 first quarter ended September 30, 2011.
Read More
Read More
10/27/2011 - Lannett To Report Fiscal 2012 First-Quarter Financial Results and Host Conference Call On Thursday, November 3, 2011
Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced that the company will release its fiscal 2012 first-quarter financial results on Thursday, November 3, 2011.
Read More
View the Webcast
Read More
View the Webcast
10/24/2011 - Lannett Receives FDA Approval For Diethylpropion HCL Extended Release Tablets, 75 MG
Lannett Company, Inc. (NYSE AMEX:LCI), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Diethylpropion HCl Extended Release Tablets, 75 mg.
Read More
Read More
10/14/2011 - Lannett Launches Three Recently Approved Products
Lannett Company, Inc. (NYSE AMEX:LCI), today announced that it has commenced shipping three products - Diethylpropion Tablets 25mg, Phentermine HCI Capsules 37.5mg and Loxapine Capsules 5 mg, 10 mg, 25 mg and 50 mg - recently approved by the U.S. Food and Drug Administration (FDA).
Read More
Read More
09/27/2011 - Lannett Receives FDA Approval For Loxapine Capsules, 5 MG, 10 MG, 25 MG And 50 MG
Lannett Company, Inc. (NYSE AMEX:LCI), today announced it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) of Loxapine Capsules, 5 mg, 10 mg, 25 mg and 50 mg, which are therapeutically equivalent to the reference listed drug, Loxitane Capsules, 5 mg, 10 mg, 25 mg and 50 mg from Watson Pharmaceuticals.
Read More
Read More
09/13/2011 - Lannett To Present At UBS Global Life Sciences Conference
Lannett Company, Inc. (NYSE AMEX:LCI), today announced that the company will present at the UBS Global Life Sciences Conference on Monday, September 19, 2011 at 11 a.m. ET (8 a.m. PT) at the Grand Hyatt New York Hotel.
Read More
View the Webcast
Read More
View the Webcast
09/12/2011 - Lannett Company CEO Purchase Stock
Lannett Company, Inc. (NYSE AMEX:LCI), a manufacture of generic pharmaceuticals, today announced that Arthur Bedrosian, the company's president and CEO, purchased 20,467 shares of Lannett Company common stock in the open market on September 9, 2011.
Read More
Read More
09/07/2011 - Lannett Reports Fiscal 2011 Fourth Quarter, Full-Year Financial Results
Lannett Company, Inc. (NYSE AMEX:LCI), today reported financial results for the fiscal 2011 fourth quarter and full year ended June 30, 2011.
Read More
Read More
09/01/2011 - Lannett To Report Fiscal 2011 Fourth-Quater And Full-Year Financial Results And Host Conference Call On Wednesday, September 7, 2011
Lannett Company, Inc. (NYSE AMEX:LCI), a manufacture of generic pharmaceuticals, today announced that the company will release its fiscal 2011 fourth-quarter and full-year financial results on Wednesday, September 7, 2011.
Read More
View the Webcast
Read More
View the Webcast
08/16/2011 - Lannett Appoints Jeffrey Farber As Vice Chairman
Lannett Company, Inc. (NYSE AMEX:LCI) today announced the appointment of Jeffrey Farber as Vice Chairman of the Board.
Read More
Read More
08/11/2011 - Lannett Launches Morphine Sulfate Oral Solution
Lannett Company, Inc. (NYSE AMEX:LCI) today announced that it has commenced shipping of its Morphine Sulfate Oral Solution product.
Read More
Read More
08/08/2011 - Lannett Names Martin Galvan As Chief Financial Officer
Lannett Company, Inc. (NYSE AMEX:LCI) today announced the appointment of Martin P. Galvan as chief financial officer, succeeding Keith Ruck, who recently left the company.
Read More
Read More
08/02/2011 - Lannett Announces Chief Financial Officer Resignation
Lannett Company, Inc. (NYSE AMEX:LCI) today announced that Keith Ruck has resigned as chief financial officer to pursue other interests.
Read More
Read More
07/29/2011 - Lannett Receives FDA Approval For Phentermine Resin Extended-Release Capsules, 15 MG And 30 MG
Lannett Company, Inc. (NYSE AMEX:LCI) today announced that the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules, 15 MG and 30 MG, representing the fourth product approval the company has received in the last five weeks.
Read More
Read More
07/20/2011 - Lannett Receives FDA Approval For Phentermine HCL Capsules, 37.5 MG
Lannett Company, Inc. (NYSE AMEX:LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) of Phentermine HCl Capsules, 37.5 mg.
Read More
Read More
07/18/2011 - Lannett Receives FDA Approval For Diethylproprion HCL Tablets, 25 MG
Lannett Company, Inc. (NYSE AMEX:LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) of Diethylproprion HCl Tablets, 25 mg.
Read More
Read More
07/05/2011 - Lannett Announces Appointment Of Vice President-Logistics And CIO
Lannett Company, Inc. (NYSE AMEX:LCI) today announced the promotion of Robert Ehlinger to vice president of logistics and chief information officer.
Read More
Read More
06/24/2011 - Lannett Receives FDA Approval For Morphine Sulfate Oral Solution NDA
Lannett Company, Inc. (NYSE AMEX:LCI) today announced that the U.S. Food and Drug Administration(FDA) has approved the company's 505(b)(2) New Drug Application(NDA) for Morphine Sulfate Oral Solution on June 23, 2011.
Read More
Read More
06/06/2011 - Lannett Announces Revised FDA PDUFA Date For Morphine Sulfate Oral Solution NDA
Lannett Company, Inc. (NYSE AMEX:LCI) announced today that the U.S.Food and Drug Administration (FDA) has issued a revised Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2011 for the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution.
Read More
Read More
06/01/2011 - Lannett Announces Changes To Board Of Directors
The Board of Directors of Lannett Company, Inc. (NYSE AMEX:LCI) today announced that effective July 1, 2011 Ronald A. West will become Chairman of the Board, succeeding William Farber who will remain with the Company as Chairman Emeritus.
Read More
Read More
05/18/2011 - Lannett CEO Purchases Shares Of Company In Open Market
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced Arthur Bedrosian, president and chief executive officer, purchased 5,000 shares of the company's common stock in the open market on May 16, 2011.
Read More
Read More
05/11/2011 - Lannett Reports Fiscal 2011 Third Quarter Financial Results
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today reported financial results for the fiscal 2011 third quarter and first nine months ended March 31, 2011.
Read More
Read More
05/06/2011 - Lannett To Report Fiscal 2011 Third-Quarter Financial Results And Host Conference Call On Wednesday, May 11, 2011 at 4:30 p.m Eastern (1:30 p.m. Pacific).
Lannett Company, Inc. (NYSE AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that the company will release its fiscal 2011 third-quarter financial results on Wednesday, May 11, 2011.
Read More
View the Webcast
Read More
View the Webcast
03/22/2011 - Lannett Announces Positive Results Of Facilities Inspection
Lannett Company, Inc. (AMEX:LCI), today said that the U.S. Food and Drug Administration (FDA) recently completed an inspection of the company's manufacturing facility in Philadelphia, Pennsylvania and Cody, Wyoming.
Read More
Read More
03/08/11 - Lannett To Present At ROTH 23rd Annual Orange County Growth Stock Conference
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the company will present at the ROTH OC Growth Stock Conference on Tuesday, March 15, 2011 at 9 a.m PT (12 p.m. ET) at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.
Read More.
View the Webcast
Read More.
View the Webcast
03/04/2011 - Lannett Comments On News Article
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today commented on a recent Bloomberg News story, Drugmakers Failing More Plant Inspections Under Obama's FDA, in which a number of drug manufacturing companies, including Lannett, are mentioned as having failed a high number of inspections by FDA inspectors from fiscal 2000 through the year ended Sept. 30, 2010.
Read More
Read More
02/10/2011 - Lannett Reports Fiscal 2011 Second Quarter Financial Results
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today reported financial results for the fiscal 2011 second quarter and first six months ended December 31, 2010.
Read More
Read More
02/04/2011 - Lannett To Report Fiscal 2011 Second-Quarter Financial Results And Host Conference Call On Thursday, February 10
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that the company will release its fiscal 2011 second-quarter finalcial results on Thursday, February 10, 2011. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern (1:30 p.m. Pacific) to review the company's financial results and answer questions.
View the Webcast
View the Webcast
02/03/11 - Lannett To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, February 10
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that the company will release its fiscal 2011 second-quarter financial results on Thursday, February 10, 2011.
Read More.
Read More.
02/01/11 - Lannett Announces Appointment Of Chief Operating Officer
Lannett Company, Inc. (AMEX:LCI), today announced the promotion of William F. Schreck to chief operating officer, effective immediately.
Read More.
Read More.
02/01/11 - Lannett Provides Update On Morphine Sulfate New Drug Application.
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that it recently met with the U.S. Food and Drug Administration(FDA) to discuss the status of the company's New Drug Application(NDA) for Morphine Sulfate Oral Solution as well as other pending product applications.
Read More.
Read More.
